The “Tricky Business” of Identifying Mechanisms of Resistance to Anti–PD-1

James S. Wilmott; Helen Rizos; Richard A Scolyer; Georgina V. Long

doi:10.1158/1078-0432.ccr-17-0669

Abstract

1 min read

Resistance to immune checkpoint inhibitors can vary between patients and among metastases. Understanding the genomic, transcriptomic, and microenvironmental factors that contribute to this variability will reveal the mechanisms that tumors utilize to evade the therapeutic effects of checkpoint inhibitor immunotherapies and will enable us to develop strategies to overcome them. <i>Clin Cancer Res; 23(12); 2921-3. ©2017 AACR</i><i>See related article by Ascierto et al., p. 3168</i>.

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2017

Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma

Tuba N. Gide, James S. Wilmott, Richard A Scolyer, Georgina V. Long

Preprint2023

Data from Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma

Tuba N. Gide, James S. Wilmott, Richard A Scolyer, Georgina V. Long

Preprint2023

Data from Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma

Tuba N. Gide, James S. Wilmott, Richard A Scolyer, Georgina V. Long

Preprint2023

Data from β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma

Marina Ruiz de Galarreta, Erin Bresnahan, Pedro Molina-Sánchez, Katherine E. Lindblad, Bárbara Maier, Daniela Sia, Marc Puigvehí, Verónica Miguela, María Casanova-Acebes, Maxime Dhainaut, Carlos Villacorta-Martín, Aatur D. Singhi, Akshata Moghe, Johann von Felden, Lauren Tal Grinspan, Shuang Wang, Alice O. Kamphorst, Satdarshan P. Monga, Brian D. Brown, Augusto Villanueva, Josep M. Llovet, Miriam Mérad,

Preprint2023